Femasys Inc
Femasys Inc (FEMY) is a micro-cap medical device company focused on women’s reproductive health. The business develops minimally invasive diagnostic and procedural tools intended to address fertility and gynaecological needs. Investors should note the company’s small market capitalisation (about $27.5 million), which can mean limited liquidity, higher volatility and greater sensitivity to clinical, regulatory and financing news. Potential upside could come from successful product adoption, regulatory clearances or commercial partnerships, but these outcomes are uncertain and may take time. Financial performance for very small medical-device firms can be uneven and dependent on discrete contracts, trial results and reimbursement dynamics. This summary is educational and not investment advice; values can rise and fall and past performance is not a guide. Before deciding on FEMY, consider your risk tolerance, check the company’s filings for up-to-date results, and consult a regulated financial adviser for personalised guidance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Femasys Inc's stock with a target price of $5.17, indicating strong growth potential.
Financial Health
Femasys Inc has modest revenue and cash flow, but its profitability margins are promising.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FEMY
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage potential
Small market cap means more room for growth if products gain traction, though share prices can swing sharply and outcomes are uncertain.
Regulatory impact
Clinical data and approvals can materially affect prospects; regulatory milestones are catalysts but also carry execution risk.
Market and adoption
Addressing women’s reproductive health can tap large, underserved markets, but commercial uptake and reimbursement may take time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
